Recombinant human interleukin-3 hastens trilineage hematopoietic recovery following high-dose (7 g/m2) cyclophosphamide cancer therapy

A. M. Gianni, S. Siena, M. Bregni, M. Di Nicola, F. Peccatori, M. Magni, F. Ravagnani, I. Sklenar, G. Bonadonna

Research output: Contribution to journalArticle

Abstract

Background: Interleukin-3, a recombinant cytokine with multilineage stimulatory effect on hematopoietic cells, was administered to 22 previously untreated breast cancer patients following high-dose therapy with cyclophosphamide (7 g/m2). Patients and methods: The growth factor, administered through continuous intravenous infusion at 1 (3 patients), 2.5 (3 patients), 5 (10 patients) and 10 μg/kg/day (6 patients), was well tolerated up to 5 μg/kg/day. Results: Nausea, vomiting, fever and headache prevented administration of the intended dose to all 6 patients in the 10 μg/kg/day cohort. At the maximal tolerable dose (5 μg/kg/day) the growth factor significantly accelerated granulocyte, platelet and reticulocyte recovery as compared to matched historical controls who received high-dose cyclophosphamide without cytokine infusion. Moreover, no platelet transfusions and fewer erythrocyte transfusions were required in interleukin 3-treated patients. In contrast to GM-CSF and G-CSF, interleukin 3 showed no effect on the mobilization of hematopoietic progenitor cells in the peripheral blood. Conclusions: Interleukin-3 represents a well-tolerated cytokine, clinically useful for accelerating trilineage hematopoietic recovery following severely myelotoxic treatments such as high-dose cyclophosphamide.

Original languageEnglish
Pages (from-to)759-766
Number of pages8
JournalAnnals of Oncology
Volume4
Issue number9
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology
  • Hematology

Fingerprint Dive into the research topics of 'Recombinant human interleukin-3 hastens trilineage hematopoietic recovery following high-dose (7 g/m2) cyclophosphamide cancer therapy'. Together they form a unique fingerprint.

  • Cite this